Tweet
Communiqué de l'ambassade des USA à Alger:
تهانينا للباحث الجزائري الدكتور سليم بوقرموح، وهو من ضمن الفريق الذي طوّر لقاحاً مرشحاً ضد كوفيد-19 يستخدم تقنية تُعرف باسم mRNA. الدكتور بوقرموح يشغل منصب مدير مساعد للأبحاث في تطوير اللقاحات في شركة الصناعة الصيدلانية الأمريكية فايزر، وتحصل على شهادة طب من جامعة الجزائر عام 1996، قبل القيام بأبحاث ما بعد الدكتوراه في كلية هارفارد للطب في وقت لاحق. وفي التاسع من نوفمبر أعلنت شركة فايزر وشريكتها الألمانية BioNTech أن المرحلة الثالثة للقاح كانت فعالة بنسبة تزيد عن 90 ٪ في الوقاية من عدوى كوفيد-19.
Congratulations to Algerian researcher Dr. Salim Bouguermouh, who was part of the team which developed an mRNA-based Covid-19 vaccine candidate! Dr. Bouguermouh, who is associate director of vaccine clinical research and development at American pharmaceutical company Pfizer, graduated from medical school at the University of Algiers in 1996, and later did his postdoctoral research at Harvard Medical School. On November 9, Pfizer and its German partner BioNTech announced their Phase III vaccine study with more than 43,000 volunteers was more than 90% effective in preventing Covid-19 infection.
Congratulations to Algerian researcher Dr. Salim Bouguermouh, who was part of the team which developed an mRNA-based Covid-19 vaccine candidate! Dr. Bouguermouh, who is associate director of vaccine clinical research and development at American pharmaceutical company Pfizer, graduated from medical school at the University of Algiers in 1996, and later did his postdoctoral research at Harvard Medical School. On November 9, Pfizer and its German partner BioNTech announced their Phase III vaccine study with more than 43,000 volunteers was more than 90% effective in preventing Covid-19 infection.
Commentaire